FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:189-191 July 9, 2009 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fong, P. C. PubMed Citation

In this issue of the Journal, Fong et al. report the results of a phase 1 trial of a new cancer therapy involving 60 patients (ClinicalTrials.gov number, NCT00516373 [ClinicalTrials.gov] ).¹ Readers may be surprised by the editors' decision to publish a small early-stage trial, but this trial not only reports important results — it also points to a new direction in the development of anticancer drugs. Modern cancer-drug discovery focuses on finding new therapies with few side effects by leveraging advances in the understanding of cancer biology, but barriers to success are substantial. The story behind the report by Fong et . . . [Full Text of this Article]

Source Information

From the Department of Surgery, Brigham and Women's Hospital, and the Department of Cancer Biology, Dana–Farber Cancer Institute (J.D.I.); and the Department of Medical Oncology, Dana–Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School (D.P.S.) — all in Boston.

This article (10.1056/NEJMe0903044) was published on June 24, 2009, at NEJM.org.

This article has been cited by other articles:

• (2009). Olaparib for Cancers Associated with BRCA Mutations. JWatch Oncology and Hematology 2009: 2-2 [Full Text]